
With significant technology advances in ECG recording through the years, the need to expand on traditional monitoring baselines-and include new variables such as time when designing clinical trial protocols-is important.
With significant technology advances in ECG recording through the years, the need to expand on traditional monitoring baselines-and include new variables such as time when designing clinical trial protocols-is important.
The US FDA, in open meetings, stated the Thorough QT trial "must" be replaced.
The sponsor of a recent Phase II global study, conducted at more than 50 sites, invested in a centralized digital pathology core lab to ensure a homogenous and representative study population.
The responsibilities regarding CV safety for drug developers are constantly evolving.
Centralized approach for Phase III studies enhances the quality and integrity of collected data.
Published: February 13th 2025 | Updated: March 4th 2025
Published: February 19th 2025 | Updated: February 26th 2025
Published: March 24th 2023 | Updated:
Published: April 28th 2021 | Updated:
Published: July 26th 2024 | Updated:
Published: January 31st 2024 | Updated: